Exchange: NASDAQ·Updated 07:30 PM EDT
BIIB logo

BIIB Biogen Inc

$225.71
$7.28
(3.33%)
Today
Closed $225.71
$0.00
(0.00%)
After Hours
EarningsOct 28
Mkt Cap$32.27B
Vol815,008.00

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
42

Bearish Sentiment

How do you feel about BIIB?

doctordinero
$BIIB Unusually high call volume on the Biogen Jan 250s today. 700+ contracts added. GLTA $IBB $GILD $MRNA
1
theoptionsplug
$BIIB got a MASSIVE ATM call order expiring in March! Reclaimed the previous resistance zone as support (with the 50DMA being respected) - looks great to shoot towards $229!
jewell69
$BIIB b 10/2 just 13 220.39 s just now 10/7 2:28 pm edt 223.70 BAMB! HERE ! I don't have the size of account that Robin or Grandpa has
KryptonResearch14
$BIIB Biogen’s 52-week Phase 2 data for litifilimab in cutaneous lupus, presented at EADV Friday, shows the response curves deepening late. Clear or almost clear skin: 19.0% at week 24, 27.2% at week 52. Disease activity down 70% or more: 21.7% to 28.8%. In a lifelong disease with no approved targeted treatment, that shape matters. New responders are still converting at a year, not just early wins holding. The trial enrolled 93 adults who had not responded to, or could not tolerate, standard antimalarials. Patients who crossed over from placebo at week 24 saw onset as early as four weeks. FDA granted Breakthrough Therapy in January; the Phase 3 part of AMETHYST reads in the first half of 2027. Shares closed at 219.88 Friday, down 1.3%, the fourth straight losing session, about 5% off the Sept 28 high.
OnlyFibs
$BIIB | Snapshot 📊⚡ • Business: Biogen Inc., a biopharmaceutical leader focused on developing and delivering innovative therapies for neurological, rare, and immune-mediated diseases. • Financial Health & Pipeline: Expanding global commercial rollout for Leqembi (Alzheimer's) and Spinraza HD, coupled with new revenue streams from Apellis portfolio integration (Syfovre/Empaveli). • Bias & Conviction: Bullish Macro Base | High Conviction (Multi-month rounding bottom on the weekly frame backed by $438K LEAP call sweep above ask). 🎯 Key Levels: 🐂 Bull Trigger: $226.00 / $242.00 🚀 Targets: $242.00 / $265.00 / $285.00+ 🛡️ Support: $219.00 / $208.00 ⚠️ Risk: $208.00 / $200.00 🔥 Options Flow: • 🟢 01/15/2027 $240.0 Call ($438.3K Sweep | +9.59% OTM Opening Sweep Above Ask) #BIIB #biotech #healthcare #stocks #hovdid
jewell69
$BIIB day trade for 25.00 bottom line profit (yawn) but it closed down to 215.50 2 new topics: $DIA dow jones 30. worst week 9/18/26 since 3/20/26 but on the bright side oil ... not sure brent or w texas back down under 100; about 99.38 $USO $XLE

Advertisement|Remove ads.